ALECENSA® (alectinib) may work when prior crizotinib treatment stops working or can no longer be tolerated

The effectiveness of ALECENSA in people who have taken the ALK inhibitor crizotinib is based on 2 studies that measured response to treatment (response rate and duration of response).

Results from the 2 studies have shown ALECENSA effectively shrank tumors in some people with ALK+ mNSCLC who have taken crizotinib but whose mNSCLC worsened.

Tumors shrank in up to 44% of people treated with ALECENSA (38% in Study 1 and 44% in Study 2)

In Study 1, in people whose ALK+ mNSCLC tumors initially responded to ALECENSA, tumor response continued for a median of 7.5 months.

In Study 2, in people whose ALK+ mNSCLC tumors initially responded to ALECENSA, tumor response continued for a median of 11.2 months. 

ALECENSA may work in existing ALK+ mNSCLC brain tumors

In 2 studies, ALECENSA showed the ability to shrink ALK+ mNSCLC tumors that had spread to the brain in people who had taken crizotinib.

Tumor response in the central nervous system continued for a median of 9.1 months in people who had ALK+ mNSCLC tumors that had spread to the brain and who responded to treatment.

It is important to know that a complete response does not mean the cancer has been cured.

Join Staying Positive

Sign up for Staying Positive, an ALECENSA Support Program, for additional tips and resources on living with ALK+ mNSCLC.

The ALK Positivity Videos

See how real people stay positive and don't let their diagnoses define them.

Talk With Your Doctor

Click here for some helpful questions you should ask your doctor about ALECENSA.